JAGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Jaguar Health Inc (JAGX) is not a strong buy for a beginner investor with a long-term strategy at this time. The company's financial performance is weak, technical indicators are mixed, and there are no significant positive trading signals or catalysts to justify immediate investment. It is better to monitor the stock for further developments.
The MACD is positive and expanding, suggesting a bullish momentum. However, RSI is neutral at 49.488, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are at 0.576 (S1) and 0.675 (R1), with the stock currently trading near the pivot point of 0.625.
Jaguar Health is focusing on developing crofelemer for intestinal failure and has secured non-dilutive capital. Promising initial clinical data for crofelemer and plans to file an NDA with the FDA for microvillus inclusion disease in 2027 could be long-term catalysts.
The stock also has a high probability (-17.05%) of declining over the next month based on candlestick pattern analysis.
In Q3 2025, revenue dropped by -0.80% YoY to $3,083,000. Net income decreased by -3.57% YoY to -$9,502,000, and EPS fell significantly by -76.11% YoY to -6.28. Gross margin slightly improved to 82.74%, up 0.18% YoY.
No recent analyst rating or price target changes are available for JAGX.
